JP2021000056A - ナットウキナーゼを含む経口組成物 - Google Patents
ナットウキナーゼを含む経口組成物 Download PDFInfo
- Publication number
- JP2021000056A JP2021000056A JP2019116666A JP2019116666A JP2021000056A JP 2021000056 A JP2021000056 A JP 2021000056A JP 2019116666 A JP2019116666 A JP 2019116666A JP 2019116666 A JP2019116666 A JP 2019116666A JP 2021000056 A JP2021000056 A JP 2021000056A
- Authority
- JP
- Japan
- Prior art keywords
- nattokinase
- hesperidin
- oral composition
- black ginger
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940086319 nattokinase Drugs 0.000 title claims abstract description 71
- 108010073682 nattokinase Proteins 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 55
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 53
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 35
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 34
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 34
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 34
- 229940025878 hesperidin Drugs 0.000 claims abstract description 34
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 34
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 27
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 25
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 23
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 23
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000005493 rutin Nutrition 0.000 claims abstract description 23
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 23
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960004555 rutoside Drugs 0.000 claims abstract description 23
- 235000020708 ginger extract Nutrition 0.000 claims abstract description 19
- 229940002508 ginger extract Drugs 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 17
- 241000234314 Zingiber Species 0.000 claims description 14
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 14
- 235000008397 ginger Nutrition 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 2
- 238000003860 storage Methods 0.000 abstract description 18
- -1 glucosyl hesperidin Chemical compound 0.000 abstract description 4
- 230000006866 deterioration Effects 0.000 abstract 2
- 229940108690 glucosyl hesperidin Drugs 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108010025899 gelatin film Proteins 0.000 description 9
- 244000063299 Bacillus subtilis Species 0.000 description 8
- 235000014469 Bacillus subtilis Nutrition 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 235000001727 glucose Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000013557 nattō Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014048 cultured milk product Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 125000000953 rutinose group Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- PFPQMWRASYNLMZ-LGIMBNBCSA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PFPQMWRASYNLMZ-LGIMBNBCSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 241000395050 Kaempferia parviflora Species 0.000 description 1
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 1
- 241000229722 Perilla <angiosperm> Species 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000020235 chia seed Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
項1. (A)ナットウキナーゼ、並びに(B)ブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及びルチンよりなる群から選択される少なくとも1種を含有する、経口組成物。
項2. 食品である、項1に記載の経口組成物。
項3. (A)ナットウキナーゼに、(B)ブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及びルチンよりなる群から選択される少なくとも1種を共存させる、ナットウキナーゼの活性低下の抑制方法。
項4. ブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及びルチンよりなる群から選択される少なくとも1種を有効成分とする、ナットウキナーゼの活性低下抑制剤。
本発明の経口組成物は、ナットウキナーゼ((A)成分と表記することもある)、並びにブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及びルチンよりなる群から選択される少なくとも1種((B)成分と表記することもある)を含有することを特徴とする。以下、本発明の経口組成物について詳述する。
本発明の経口組成物はナットウキナーゼを含有する。ナットウキナーゼとは、納豆菌が産生するフィブリン分解作用を有する酵素である。
本発明の経口組成物は、ブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及び/又はルチンを含有する。これらの成分を含むことにより、経時的なナットウキナーゼの活性低下を抑制でき、優れた保存安定性を備えさせることが可能になる。
ブラックジンジャーの抽出物とは、ブラックジンジャーを抽出原料として抽出処理を行うことにより得られる成分である。ブラックジンジャーとは、黒ショウガとも称されており、ショウガ科バンウコン属の植物(Kaempferia parviflora)である。
ヘスペリジンとは、ヘスペレチンをアグリコンとし、これにルチノースが結合した化合物である。
α−リノレン酸は、ω3脂肪酸の一種であり、二重結合数が3の多価不飽和脂肪酸である。
ルチンとは、ケルセチン配糖体の一種である。本発明では、精製されたルチンを使用してもよいが、ルチンを含有する植物抽出物等を使用してもよい。
本発明の経口組成物は、前述する(A)及び(B)成分に加えて、他の栄養成分や薬理成分を含有していてもよい。このような栄養成分や薬理成分としては、食品や内服用医薬品に使用可能なものであれば特に制限されないが、例えば、ビタミン、アミノ酸、ミネラル、糖質、植物性油脂、植物性油脂、脂肪酸、香料、調味剤、植物エキス(ブラックジンジャーの抽出物以外)、抗酸化剤、血糖降下剤、抗コレステロール剤、免疫賦活剤等が挙げられる。これらの成分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの成分の含有量については、使用する添分の種類や経口組成物の用途等に応じて適宜設定される。
本発明の経口組成物の剤型については、経口摂取又は経口投与が可能であることを限度として特に制限されず、固体状、半固体状、又は液体状のいずれであってもよく、該経口組成物の種類や用途に応じて適宜設定すればよい。
本発明のナットウキナーゼの活性低下の抑制方法は、(A)ナットウキナーゼに、(B)ブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及びルチンよりなる群から選択される少なくとも1種を共存させることを特徴とする。
ナットウキナーゼ粉末:「納豆菌培養エキスNSK−SD40」(株式会社日本生物.科学研究所製)
ブラックジンジャーの抽出物:「ブラックジンジャー抽出物」(丸善製薬株式会社製)、ブラックジンジャーの根茎をエタノール水溶液で抽出処理した抽出物の乾燥粉末
糖転移ヘスペリジン:「αGヘスペリジンPA−T」(東洋精糖株式会社製)、ヘスペリジンにグルコースを転移させた酵素処理ヘスペリジン
α−リノレン酸含有植物油:「シソ油」(オリザ油化株式会社製)、α−リノレン酸を55重量%含有
ルチン:「αGルチンP」(東洋精糖株式会社製)
表1に示す組成の経口組成物を調製した。得られた各経口組成物20gを透明ガラス瓶(直径30mm、高さ65mm;マルエム製スクリュー管No.6)に充填し、遮光条件下で40℃又は50℃で7日間保存した。保存後の各経口組成物について、以下の方法でゼラチン分解能を指標としてナットウキナーゼ活性を測定した。
<ナットウキナーゼ活性の判定基準>
5:ゼラチン皮膜が底まで完全に溶解している(深さ3mmまで溶解)。
4:ゼラチン皮膜が殆ど底まで溶解している(深さ2.5mm以上3mm未満まで溶解)。
3:ゼラチン皮膜が半分位の深さまで溶解している(深さ1.5mm以上2.5mm未満まで溶解)。
2:ゼラチン皮膜が少し溶解している(深さ0.5mm以上1.5mm未満まで溶解)。
1:ゼラチン皮膜がややへこむ程度溶解している(深さ0.5mm未満まで溶解)。
0:ゼラチン皮膜は溶解していない。
表2〜5に示す組成の内容液、及び表6に示す組成の剤皮(カプセル皮膜)を用いて、ソフトカプセル剤(1剤当り、内容液300mg又は400mg、剤皮150mg含有)を製造した。得られたソフトカプセル剤は、保存によるナットウキナーゼの活性低下を効果的に抑制できていた。
Claims (4)
- (A)ナットウキナーゼ、並びに(B)ブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及びルチンよりなる群から選択される少なくとも1種を含有する、経口組成物。
- 食品である、請求項1に記載の経口組成物。
- (A)ナットウキナーゼに、(B)ブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及びルチンよりなる群から選択される少なくとも1種を共存させる、ナットウキナーゼの活性低下の抑制方法。
- ブラックジンジャーの抽出物、ヘスペリジン、糖転移ヘスペリジン、α−リノレン酸、及びルチンよりなる群から選択される少なくとも1種を有効成分とする、ナットウキナーゼの活性低下抑制剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019116666A JP7429503B2 (ja) | 2019-06-24 | 2019-06-24 | ナットウキナーゼを含む経口組成物 |
PCT/JP2020/022947 WO2020262004A1 (ja) | 2019-06-24 | 2020-06-11 | ナットウキナーゼを含む経口組成物 |
JP2023217033A JP2024023819A (ja) | 2019-06-24 | 2023-12-22 | ナットウキナーゼを含む経口組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019116666A JP7429503B2 (ja) | 2019-06-24 | 2019-06-24 | ナットウキナーゼを含む経口組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023217033A Division JP2024023819A (ja) | 2019-06-24 | 2023-12-22 | ナットウキナーゼを含む経口組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021000056A true JP2021000056A (ja) | 2021-01-07 |
JP7429503B2 JP7429503B2 (ja) | 2024-02-08 |
Family
ID=73993551
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019116666A Active JP7429503B2 (ja) | 2019-06-24 | 2019-06-24 | ナットウキナーゼを含む経口組成物 |
JP2023217033A Pending JP2024023819A (ja) | 2019-06-24 | 2023-12-22 | ナットウキナーゼを含む経口組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023217033A Pending JP2024023819A (ja) | 2019-06-24 | 2023-12-22 | ナットウキナーゼを含む経口組成物 |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP7429503B2 (ja) |
WO (1) | WO2020262004A1 (ja) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002291436A (ja) * | 2001-03-29 | 2002-10-08 | Oyama Tofu Kk | そばとろ納豆 |
JP2006151952A (ja) * | 2004-11-05 | 2006-06-15 | Oto Corporation:Kk | 高脂血症乃至高尿酸血症改善剤、及び、健康食品 |
JP2007091693A (ja) * | 2005-09-30 | 2007-04-12 | Oriza Yuka Kk | 保湿用組成物 |
JP2010500382A (ja) * | 2006-08-16 | 2010-01-07 | マーリン ニュートラシューティカルズ, インコーポレイテッド | 眼疾患の治療 |
US20100135919A1 (en) * | 2006-08-10 | 2010-06-03 | Jon Barron | Proteolytic enzyme formulations |
JP2014114216A (ja) * | 2012-12-06 | 2014-06-26 | Oriza Yuka Kk | エストラジオール生成促進剤 |
JP2014185109A (ja) * | 2013-03-23 | 2014-10-02 | Oriza Yuka Kk | 免疫賦活剤 |
CN104367624A (zh) * | 2013-08-13 | 2015-02-25 | 刘炳喜 | 一种含有红曲的复方制剂 |
JP2016124832A (ja) * | 2015-01-05 | 2016-07-11 | オリザ油化株式会社 | 筋肉細胞におけるエネルギー代謝活性化剤 |
JP2017031120A (ja) * | 2015-08-05 | 2017-02-09 | オリザ油化株式会社 | TNF−α及びIL−6産生抑制剤及びそれを用いた筋肉炎症抑制剤 |
JP2017031121A (ja) * | 2015-08-05 | 2017-02-09 | オリザ油化株式会社 | Ampk活性化剤 |
JP2017078032A (ja) * | 2015-10-19 | 2017-04-27 | オリザ油化株式会社 | 運動機能の向上剤 |
CN107897716A (zh) * | 2017-10-19 | 2018-04-13 | 长沙湘资生物科技有限公司 | 一种橘皮纳豆产品 |
JP2019001763A (ja) * | 2017-06-19 | 2019-01-10 | 株式会社東洋新薬 | 血中コレステロール上昇抑制組成物 |
-
2019
- 2019-06-24 JP JP2019116666A patent/JP7429503B2/ja active Active
-
2020
- 2020-06-11 WO PCT/JP2020/022947 patent/WO2020262004A1/ja active Application Filing
-
2023
- 2023-12-22 JP JP2023217033A patent/JP2024023819A/ja active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002291436A (ja) * | 2001-03-29 | 2002-10-08 | Oyama Tofu Kk | そばとろ納豆 |
JP2006151952A (ja) * | 2004-11-05 | 2006-06-15 | Oto Corporation:Kk | 高脂血症乃至高尿酸血症改善剤、及び、健康食品 |
JP2007091693A (ja) * | 2005-09-30 | 2007-04-12 | Oriza Yuka Kk | 保湿用組成物 |
US20100135919A1 (en) * | 2006-08-10 | 2010-06-03 | Jon Barron | Proteolytic enzyme formulations |
JP2010500382A (ja) * | 2006-08-16 | 2010-01-07 | マーリン ニュートラシューティカルズ, インコーポレイテッド | 眼疾患の治療 |
JP2014114216A (ja) * | 2012-12-06 | 2014-06-26 | Oriza Yuka Kk | エストラジオール生成促進剤 |
JP2014185109A (ja) * | 2013-03-23 | 2014-10-02 | Oriza Yuka Kk | 免疫賦活剤 |
CN104367624A (zh) * | 2013-08-13 | 2015-02-25 | 刘炳喜 | 一种含有红曲的复方制剂 |
JP2016124832A (ja) * | 2015-01-05 | 2016-07-11 | オリザ油化株式会社 | 筋肉細胞におけるエネルギー代謝活性化剤 |
JP2017031120A (ja) * | 2015-08-05 | 2017-02-09 | オリザ油化株式会社 | TNF−α及びIL−6産生抑制剤及びそれを用いた筋肉炎症抑制剤 |
JP2017031121A (ja) * | 2015-08-05 | 2017-02-09 | オリザ油化株式会社 | Ampk活性化剤 |
JP2017078032A (ja) * | 2015-10-19 | 2017-04-27 | オリザ油化株式会社 | 運動機能の向上剤 |
JP2019001763A (ja) * | 2017-06-19 | 2019-01-10 | 株式会社東洋新薬 | 血中コレステロール上昇抑制組成物 |
CN107897716A (zh) * | 2017-10-19 | 2018-04-13 | 长沙湘资生物科技有限公司 | 一种橘皮纳豆产品 |
Non-Patent Citations (7)
Title |
---|
GNPD - ADULT MILK POWDER, [ONLINE], ID# 826580, 2007, [RETRIEVED ON 2020.08.14], JPN6020031101, ISSN: 0005058058 * |
GNPD - DIETARY SUPPLEMENT CAPSULES, [ONLINE], ID# 1808740, 2012, [RETRIEVED ON 2020.08.17], JPN6020031105, ISSN: 0005058062 * |
GNPD - EPA X DHA PLUS CAPSULE, [ONLINE], ID# 2927069, 2015, [RETRIEVED ON 2020.08.17], JPN6020031104, ISSN: 0005058061 * |
GNPD - GOOD CHOICE 40 (FLOWER), [ONLINE], ID# 639260, 2007, [RETRIEVED ON 2020.08.17], JPN6020031102, ISSN: 0005058059 * |
GNPD - MULTIVITAMIN & MINERAL PERFECT SUPPLEMENT, [ONLINE], ID# 4885617, 2017, [RETRIEVED ON 2020.08, JPN6020031103, ISSN: 0005058060 * |
GNPD - PREMIUM NATTOKINASE SOFT CAPSULES, [ONLINE], ID# 4886217, 2017, [RETRIEVED ON 2020.08.17], JPN6020031100, ISSN: 0005058057 * |
堀田 幸子, 小谷 明司, ブラックジンジャーについて, NEW FOOD INDUSTRY, 2013, VOL.55, NO.1, P.29-32, JPN6020031106, ISSN: 0005058063 * |
Also Published As
Publication number | Publication date |
---|---|
JP7429503B2 (ja) | 2024-02-08 |
WO2020262004A1 (ja) | 2020-12-30 |
JP2024023819A (ja) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1902722B1 (en) | Agent for elevating adiponectin concentration | |
JP2013032352A (ja) | フルクトース吸収阻害剤 | |
JP6335508B2 (ja) | 成長ホルモン分泌促進剤 | |
JP2007091631A (ja) | 抗ピロリ菌剤及びこれを含有する飲食物 | |
KR101974442B1 (ko) | 사이클로덱스트린을 포함하는 카테킨 생체 이용률 증진제 | |
KR100815171B1 (ko) | 시클로옥시게나아제 저해제 및 그를 함유하는 음식품 | |
JP5545692B2 (ja) | キサンチンオキシダーゼ阻害剤及び血漿中尿酸値低下剤 | |
KR102350102B1 (ko) | 항산화 활성이 증진된 발효 홍삼 추출물을 유효성분으로 함유하는 항염증용 조성물 | |
JP7429503B2 (ja) | ナットウキナーゼを含む経口組成物 | |
KR100972167B1 (ko) | 아라리아 에스쿠렌타 추출물을 유효성분으로 포함하는항산화 및 면역질환 예방 및 치료용 조성물 | |
JP4744297B2 (ja) | 糖脂質含有組成物、その用途およびその製造方法 | |
JP7486311B2 (ja) | 血中コレステロール低下用組成物 | |
JP2023032416A (ja) | 血管柔軟性改善用組成物、血管内皮機能改善用組成物、血小板凝集抑制用組成物、血流改善用組成物、経口組成物 | |
JP7016074B2 (ja) | 中性脂肪及びコレステロール低減用組成物 | |
JP7398214B2 (ja) | サラシア属植物の抽出物を含有する経口組成物 | |
JP4988166B2 (ja) | キサンチンオキシダーゼ阻害剤 | |
JP2016190801A (ja) | 難消化性グルカンを含有する血中中性脂肪上昇抑制剤および血中レムナント様リポ蛋白コレステロール上昇抑制剤 | |
JP2022077167A (ja) | ナットウキナーゼを含む経口組成物 | |
JP5758563B2 (ja) | ヒアルロニダーゼ活性阻害剤、及び腫瘍壊死因子産生抑制剤 | |
JP2022077166A (ja) | ナットウキナーゼを含む経口組成物 | |
JP7499021B2 (ja) | 経口組成物 | |
JP2010241725A (ja) | ヒアルロン酸産生促進剤 | |
JP2022077168A (ja) | ナットウキナーゼを含む経口組成物 | |
KR20230139906A (ko) | 폐기능 개선 효과가 증진된 홍삼 및 개복숭아 추출물을 유효성분으로 함유하는 조성물 | |
JP2024047661A (ja) | 食後の尿酸値上昇抑制用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230516 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230913 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231017 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240129 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7429503 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |